LivaNova PLC (LIVN)

Currency in USD
69.06
-1.22(-1.73%)
Real-time Data·
LIVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
68.6569.11
52 wk Range
32.4871.92
Key Statistics
Prev. Close
70.27
Open
69.11
Day's Range
68.65-69.11
52 wk Range
32.48-71.92
Volume
8.27K
Average Volume (3m)
678.26K
1-Year Change
65.5321%
Book Value / Share
21.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LIVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
79.91
Upside
+15.71%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

LivaNova PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

LivaNova PLC Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova’s aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LivaNova PLC SWOT Analysis


Innovation Pipeline
Explore LivaNova's product development strategy, focusing on the Essenz heart-lung machine and potential breakthroughs in sleep apnea and depression treatments
Market Dynamics
Delve into LivaNova's positioning in the cardiopulmonary and neuromodulation segments, examining competitive pressures and expansion opportunities
Financial Outlook
Analysts project 6-7% organic growth for LivaNova, with potential to exceed this range. Average price target from analysts stands at $56.50
Regulatory Landscape
Uncover the impact of regulatory decisions on LivaNova's growth prospects, including FDA submissions and Medicare coverage reconsiderations
Read full SWOT analysis

LivaNova PLC Earnings Call Summary for Q4/2025

  • LivaNova Q4 2025 EPS of $0.86 beat estimates of $0.81; revenue hit $360.9M vs. $353.23M forecast, marking fifth year of double-digit EPS growth
  • Revenue rose 9.5% YoY on constant currency basis; adjusted operating income increased to $64M from $56M in Q4 2024; gross margin held at 68%
  • Stock declined 4.66% to $65.83 in pre-market despite earnings beat, reflecting potential investor concerns over market conditions
  • FY 2026 guidance projects EPS range of $0.87-$1.04 quarterly; revenue forecast at $1.47B driven by cardiopulmonary and epilepsy segment expansion
  • CEO McDonald emphasized innovation strategy with upcoming FDA approvals and launches in sleep apnea and depression markets to fuel growth
Last Updated: 02/25/2026, 10:24 PM
Read Full Transcript

Compare LIVN to Peers and Sector

Metrics to compare
LIVN
Peers
Sector
Relationship
P/E Ratio
−15.8x23.5x−0.5x
PEG Ratio
0.030.210.00
Price/Book
3.2x2.0x2.6x
Price / LTM Sales
2.8x2.7x3.2x
Upside (Analyst Target)
15.3%32.7%47.3%
Fair Value Upside
Unlock3.3%6.7%Unlock

Analyst Ratings

8 Buy
3 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 79.91
(+15.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold73.00+6.12%67.00MaintainFeb 27, 2026
Baird
Buy83.00+20.66%75.00MaintainFeb 26, 2026
Mizuho
Buy85.00+23.56%72.00MaintainFeb 26, 2026
Goldman Sachs
Hold73.00+6.12%66.00MaintainFeb 26, 2026
Wolfe Research
Buy80.00+16.30%70.00MaintainFeb 26, 2026

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
0.86 / 0.81
Revenue / Forecast
360.90M / 353.23M
EPS Revisions
Last 90 days

LIVN Income Statement

People Also Watch

148.53
MOH
-2.55%
203.84
ONTO
-6.52%
29.49
TDC
-3.03%
63.88
HAE
+0.88%

FAQ

What Is the LivaNova PLC (LIVN) Stock Price Today?

The LivaNova PLC stock price today is 69.06 USD.

What Stock Exchange Does LivaNova PLC Trade On?

LivaNova PLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LivaNova PLC?

The stock symbol for LivaNova PLC is "LIVN."

What Is the LivaNova PLC Market Cap?

As of today, LivaNova PLC market cap is 3.84B USD.

What Is LivaNova PLC's Earnings Per Share (TTM)?

The LivaNova PLC EPS (TTM) is -4.45.

When Is the Next LivaNova PLC Earnings Date?

LivaNova PLC will release its next earnings report on May 06, 2026.

From a Technical Analysis Perspective, Is LIVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has LivaNova PLC Stock Split?

LivaNova PLC has split 0 times.

How Many Employees Does LivaNova PLC Have?

LivaNova PLC has 3300 employees.

What is the current trading status of LivaNova PLC (LIVN)?

As of Mar 03, 2026, LivaNova PLC (LIVN) is trading at a price of 69.06 USD, with a previous close of 70.27 USD. The stock has fluctuated within a day range of 68.65 USD to 69.11 USD, while its 52-week range spans from 32.48 USD to 71.92 USD.

What Is LivaNova PLC (LIVN) Price Target According to Analysts?

The average 12-month price target for LivaNova PLC is 79.91 USD, with a high estimate of 90 USD and a low estimate of 67 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +15.71% Upside potential.

What Is the LIVN Premarket Price?

LIVN's last pre-market stock price is 68.71 USD. The pre-market share volume is 890.00, and the stock has decreased by -1.56, or -2.22%.

What Is the LIVN After Hours Price?

LIVN's last after hours stock price is 70.62 USD, the stock has decreased by 0.35, or 0.50%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.